All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know ALL.
The ALL Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the ALL Hub cannot guarantee the accuracy of translated content. The ALL Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On March 7, 2023, it was announced that nelarabine injection, a prodrug of guanine arabinoside, was approved by the U.S. Food and Drug Administration (FDA) for the treatment of T-cell acute lymphoblastic leukemia (T-ALL) and T-cell lymphoblastic lymphoma.1,2
This approval is encouraging for pediatric and young adult patients with T-ALL who have not responded to, or have relapsed following, treatment with prior chemotherapeutic agents, addressing a clinical need in this patient group.3
T-ALL is a rare and aggressive subtype of ALL which is most common in children.1 Currently, nelarabine is the only approved treatment for T-ALL in both pediatric and adult patients. The phase III COG AALL0434 trial (NCT00408005) investigating nelarabine and escalating-dose methotrexate in young patients with newly diagnosed T-cell ALL or T-cell lymphoblastic lymphoma, previously reported on the ALL hub, demonstrated promising 5-year survival outcomes; event-free survival, overall survival, and disease-free survival was 88%, 90%, and 91%, respectively.4
Educational theme | Treatment landscape of T-ALL
The treatment landscape for T-cell acute lymphoblastic leukemia (T-ALL) is evolving. Whilst many advances have been made in recent years, there remains a significant unmet need for the development of...
Results from the AALL0434 phase III trial evaluating nelarabine in newly diagnosed pediatric and young adult T-ALL
Dunsmore et al. investigated the efficacy and safety of nelarabine in children and young adults with newly diagnosed T-ALL during the...
Subscribe to get the best content related to ALL delivered to your inbox